ImmunityBio Reports 168% Revenue Growth to $44.2 Million Despite Increased Net Loss

ImmunityBio, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company generated total revenue of $44.2 million, a substantial increase of approximately 168% compared to $16.5 million in the same period last year. This growth was primarily driven by increased sales of its lead product, ANKTIVA, which has been approved for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Despite the revenue growth, ImmunityBio reported a net loss of $632.8 million for the quarter, compared to a loss of $129.7 million in the prior year, reflecting a significant increase in operating expenses and changes in fair value of financial instruments.

The company's operating costs rose to $114.0 million, up from $80.9 million in the previous year, largely due to increased research and development expenses, which totaled $68.0 million, and selling, general, and administrative expenses, which reached $45.8 million. The increase in R&D expenses was attributed to higher clinical trial costs and personnel-related expenses, while the rise in SG&A expenses was driven by increased professional service costs and marketing efforts associated with the commercialization of ANKTIVA.

In terms of strategic developments, ImmunityBio has made notable progress in expanding its market presence. The company has received regulatory approvals for ANKTIVA across five jurisdictions, including the U.S., UK, and several countries in Asia and Europe. The company also reported a cash position of $380.9 million as of March 31, 2026, a significant increase from $242.8 million at the end of 2025, bolstered by proceeds from equity offerings and the exercise of warrants. This improved liquidity is expected to support ongoing commercialization efforts and the development of additional product candidates.

Operationally, ImmunityBio has fully enrolled its pivotal trial for BCG-naïve patients with CIS and is on track for a supplemental Biologics License Application (sBLA) submission in 2026. The company also reported a 168% increase in unit sales volume of ANKTIVA compared to the same quarter last year. However, the company continues to face challenges, including a substantial accumulated deficit of $4.4 billion and ongoing negative cash flows from operations, which raise concerns about its ability to sustain operations without additional financing.

Looking ahead, ImmunityBio anticipates that it will need to secure further funding to support its operations and product development. The company plans to explore various financing options, including equity offerings and potential collaborations, to ensure it can meet its financial obligations and continue its growth trajectory. The management remains optimistic about the future, citing the potential of ANKTIVA and its pipeline of immunotherapy candidates to address significant unmet medical needs in oncology and infectious diseases.